Making Every Effort

ABSTRACT

While the majority of the world is in isolation to try to slow the spread of the virus responsible for COVID19, companies and regulatory bodies in the bio/pharma industry are facing numerous challenges and committing significant efforts to support the development of novel therapeutics and monitor supply chains. Some notable drugs and vaccines for COVID-19 in development are * Messenger RNA vaccines, from CureVac and BioNTech, are in preclinical stages. * Remdesivir, from Gilead Sciences, originally developed to treat Ebola, is in Phase III clinical trials. * SNG001, from Synairgen Research, is an inhaled formulation of interferon-beta-1a that is entering Phase II clinical trials. * Chloroquine and hydroxychloroquine are currently being investigated in clinical trials and are being donated by various companies for evaluation. The emptying of the shelves can be attributed to the, as of yet unproven, link with the drug having efficacy in the treatment of COVID-19. [...]in this current climate, it is imperative that pertinent scientific information that can be of reassurance and informative be disseminated with due diligence and care.